Total Payments
$1.4M
2024 Payments
$60,263
Companies
45
Transactions
916
Payment Breakdown by Category
Consulting$929,387 (68.6%)
Other$187,613 (13.9%)
Research$122,276 (9.0%)
Travel$90,186 (6.7%)
Food & Beverage$13,338 (1.0%)
Education$11,459 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $929,387 | 316 | 68.6% |
| Unspecified | $122,276 | 121 | 9.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $119,506 | 84 | 8.8% |
| Travel and Lodging | $90,186 | 142 | 6.7% |
| Honoraria | $52,478 | 14 | 3.9% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $15,629 | 1 | 1.2% |
| Food and Beverage | $13,338 | 237 | 1.0% |
| Education | $11,459 | 1 | 0.8% |
Payments by Type
General
$1.2M
795 transactions
Research
$122,276
121 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $240,766 | 163 | $0 (2024) |
| PFIZER INC. | $185,716 | 101 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $93,821 | 55 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $78,886 | 66 | $0 (2024) |
| Amgen Inc. | $65,126 | 69 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $65,096 | 31 | $0 (2024) |
| Celltrion, Inc. | $53,315 | 6 | $0 (2018) |
| GlaxoSmithKline, LLC. | $52,877 | 20 | $0 (2024) |
| Novartis Pharma AG | $44,675 | 21 | $0 (2020) |
| Regeneron Healthcare Solutions, Inc. | $41,079 | 43 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $60,263 | 33 | E.R. Squibb & Sons, L.L.C. ($17,937) |
| 2023 | $47,056 | 41 | AstraZeneca UK Limited ($10,488) |
| 2022 | $119,118 | 73 | Boehringer Ingelheim Pharmaceuticals, Inc. ($42,754) |
| 2021 | $83,185 | 45 | AbbVie Inc. ($17,225) |
| 2020 | $168,088 | 89 | AbbVie Inc. ($39,600) |
| 2019 | $217,523 | 156 | AbbVie, Inc. ($71,891) |
| 2018 | $370,447 | 265 | PFIZER INC. ($65,422) |
| 2017 | $288,581 | 214 | PFIZER INC. ($69,541) |
All Payment Transactions
916 individual payment records from CMS Open Payments — Page 1 of 37
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | SWEDISH ORPHAN BIOVITRUM AB | — | Consulting Fee | Cash or cash equivalent | $3,500.00 | General |
| 12/31/2024 | SWEDISH ORPHAN BIOVITRUM AB | — | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| 12/19/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| 12/17/2024 | Pacira Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $5,040.00 | General |
| 11/19/2024 | ABBVIE INC. | SKYRIZI (Biological) | Consulting Fee | Cash or cash equivalent | $3,500.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/18/2024 | ABBVIE INC. | SKYRIZI (Biological) | Consulting Fee | Cash or cash equivalent | $5,600.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/16/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $120.13 | General |
| Category: Dermatology | ||||||
| 11/16/2024 | SOBI, INC | SYNAGIS (Drug) | Food and Beverage | In-kind items and services | $29.84 | General |
| Category: IMMUNOLOGY | ||||||
| 10/02/2024 | AstraZeneca UK Limited | SAPHNELO (Biological) | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 10/02/2024 | AstraZeneca UK Limited | SAPHNELO (Biological) | Consulting Fee | Cash or cash equivalent | $75.00 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 07/15/2024 | Bayer Healthcare Pharmaceuticals Inc. | Essure (Device) | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| Category: Womens Health | ||||||
| 07/12/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $63.29 | General |
| Category: Dermatology | ||||||
| 06/30/2024 | SWEDISH ORPHAN BIOVITRUM AB | — | Consulting Fee | Cash or cash equivalent | $3,500.00 | General |
| 06/20/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $8,477.43 | General |
| 06/04/2024 | Bayer Healthcare Pharmaceuticals Inc. | Essure (Device) | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| Category: Womens Health | ||||||
| 05/20/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $3,250.00 | General |
| 05/08/2024 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $36.66 | General |
| 05/07/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $482.21 | General |
| 05/07/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $57.99 | General |
| 05/02/2024 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $44.01 | General |
| Category: Immunology | ||||||
| 05/01/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $5,100.00 | General |
| 04/19/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Travel and Lodging | Cash or cash equivalent | $5,454.90 | General |
| Category: Immunology | ||||||
| 04/19/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $65.00 | General |
| Category: Immunology | ||||||
| 04/19/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $50.00 | General |
| Category: Immunology | ||||||
| 04/19/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $30.00 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Publication support research related | Novartis Pharma AG | $19,158 | 14 |
| TOFACITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $12,100 | 11 |
| A Prospective, Open-Label, Dose-Escalation Phase 1 Study of Intra-Articular Administration of an Allogeneic Human Placental Tissue Particulate (PTP-001) for the Treatment of Knee Osteoarthritis | Bioventus LLC | $7,313 | 7 |
| M15-998 | AbbVie, Inc. | $5,550 | 1 |
| M16-063 | AbbVie, Inc. | $5,030 | 3 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $4,902 | 8 |
| Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators | Amgen Inc. | $3,967 | 1 |
| A PHASE III, MULTICENTRE, RANDOMISED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF TOCILIZUMAB IN SUBJECTS WITH GIANT CELL ARTERITIS | F. Hoffmann-La Roche AG | $2,746 | 5 |
| Etanercept monotherapy in PsA | Amgen Inc. | $2,411 | 3 |
| A PHASE III RANDOMIZED DOUBLE BLINDED PLACEBO CONTROLLED MULTICENTER STUDY OF SUBCUTANEOUS SECUKINUMAB 150MG AND 300MG IN PREFILLED SYRINGE TO EMONSTRATE EFFICACY INCLUDING INHIBITION OF STRUCTURAL DAMAGE SAFETY AND TOLERABILITY UP TO 2 YEARS IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS FUTURE 5 | Novartis Pharmaceuticals Corporation | $2,400 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $1,885 | 1 |
| Efficacy and safety of switching from adalimumab to sarilumab in patients with rheumatoid arthiritis: Results of the MONARCH open-label extension study | SANOFI-AVENTIS U.S. LLC | $1,664 | 2 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $1,499 | 2 |
| A Prospective, Open-Label, Dose-Escalation Phase 1 Study of Intra Articular Administration of an Allogeneic Human Placental Tissue Particulate (PTP-001) for the Treatment of Knee Osteoarthritis | Bioventus LLC | $1,300 | 1 |
| Depressive symptoms in patients with rheumatoid arthritis in sarilumab TARGET and MOBILITY trials and impact of treatment | SANOFI-AVENTIS U.S. LLC | $1,274 | 2 |
| ACR 2020SEAM-PSA Treatment Effects Poster | Amgen Inc. | $1,192 | 1 |
| MONARCH | SANOFI-AVENTIS U.S. LLC | $1,127 | 2 |
| Patient-Reported Outcomes with Sarilumab in Patients with Rheumatoid Arthritis are Similar Regardless of Primary or Secondary Failure with Tumor Necrosis Factor Inhibitors | SANOFI-AVENTIS U.S. LLC | $1,072 | 2 |
| A Randomized, Double-blind, Parallel, Placebo-controlled Study Assessing the Efficacy and Safety of Sarilumab Added to Non-biologic DMARD Therapy in Patients With Rheumatoid Arthritis Who Are Inadequa | SANOFI-AVENTIS U.S. LLC | $971.90 | 2 |
| A randomized, double-blind, parallel-group study assessing the efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis | GENZYME CORPORATION | $893.33 | 1 |
| PRO analysis of real-world data (2015 US National Health and Wellness Survey), and of data from TARGET and MOBILITY | SANOFI-AVENTIS U.S. LLC | $884.40 | 1 |
| TOFACITINIB SPA CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $780.00 | 1 |
| A Randomized, Double-blind, Parallel-group Study Assessing the Efficacy and Safety of Sarilumab Monotherapy Versus Adalimumab Monotherapy in Patients With Rheumatoid Arthritis | SANOFI-AVENTIS U.S. LLC | $754.80 | 1 |
| A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica | GENZYME CORPORATION | $750.00 | 2 |
| HRQOL analysis of MOBILITY, TARGET, and MONARCH | SANOFI-AVENTIS U.S. LLC | $737.00 | 1 |
| PRO analysis of MONARCH | SANOFI-AVENTIS U.S. LLC | $737.00 | 1 |
| Patient-Reported Benefits of Sarilumab Monotherapy in Adult Patients with Active Rheumatoid Arthritis: Results from an Open-Label Extension Study | SANOFI-AVENTIS U.S. LLC | $735.00 | 2 |
| Effects of Sarilumab on Patient Reported Impact of Rheumatoid Arthritis Assessed Using the RAID Scale in two Randomized Phase 3 Trials | SANOFI-AVENTIS U.S. LLC | $730.33 | 1 |
| The Impact of Rheumatoid Arthritis on Patient-Reported Outcomes: Comparison Between Sarilumab Clinical Trials and Real-World Patient Data | SANOFI-AVENTIS U.S. LLC | $723.60 | 1 |
| Differential effects of sarilumab and adalimumab on circulating biomarkers of bone resorption and cardiovascular risk and correlations with clinical and patient-reported outcomes | SANOFI-AVENTIS U.S. LLC | $714.00 | 1 |
| Exploring the Effects of Depressive Symptoms on the Efficacy of Sarilumab and Improvements in Health-Related Quality of Life | SANOFI-AVENTIS U.S. LLC | $603.00 | 1 |
| na | AbbVie, Inc. | $500.00 | 1 |
| Sarilumab and adalimumab differential effects on bone resorption and cardiovascular risk biomarkers, and predictions of treatment outcomes | SANOFI-AVENTIS U.S. LLC | $392.62 | 2 |
| Measurement properties of the minimal disease activity criteria for psoriatic arthritis | Amgen Inc. | $378.41 | 1 |
| Association Between Changes in C-reactive Protein at Week 12 With Sarilumab Therapy and Patient-reported Outcomes at Week 24 Across Three Pivotal Phase 3 Studies | SANOFI-AVENTIS U.S. LLC | $353.33 | 1 |
| : Patient-Reported Benefits and Safety of Sarilumab Monotherapy in Adult Patients with Active Rheumatoid Arthritis | SANOFI-AVENTIS U.S. LLC | $268.00 | 1 |
| Patient-Reported Outcomes with Sarilumab in Patients with Rheumatoid Arthritis | SANOFI-AVENTIS U.S. LLC | $268.00 | 1 |
| A randomized, double-blind, parallel-group study assessing the efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis | SANOFI-AVENTIS U.S. LLC | $266.05 | 1 |
| Impact of rheumatoid arthritis on patient-reported outcomes: comparison between Sarilumab clinical trials and real-world patient data ( 2017 US National Health and Wellness Survey (NHWS) and MOBILITY | SANOFI-AVENTIS U.S. LLC | $240.00 | 1 |
| Impact of Treatment on depressive symptoms in patients with rheumatoid arthritis | SANOFI-AVENTIS U.S. LLC | $201.00 | 1 |
| Impact of treatment in patients with rheumatoid arthritis and depressive symptoms | SANOFI-AVENTIS U.S. LLC | $201.00 | 1 |
| Effects of Sarilumab on Patient Reported Impact of Rheumatoid Arthritis Assessed Using the Rheumatoid Arthritis Impact of Disease Scale in two Randomized Phase 3 Trials | SANOFI-AVENTIS U.S. LLC | $97.60 | 1 |
| Impact of treatment in patients with rheumatoid arthritis and depressive symptoms in the MONARCH Phase 3 trial of sarilumab | SANOFI-AVENTIS U.S. LLC | $88.00 | 1 |
| Efficacy and safety of switching from adalimumab to sarilumab in patients with rheumatoid arthritis: Results of the MONARCH open-label extension study | SANOFI-AVENTIS U.S. LLC | $70.00 | 2 |
| Effects of Sarilumab on Patient-Reported Impact of Rheumatoid Arthritis Using the Rheumatoid Arthritis Impact of Disease Scale | SANOFI-AVENTIS U.S. LLC | $56.00 | 1 |
| RAID analysis of TARGET and MONARCH | SANOFI-AVENTIS U.S. LLC | $37.33 | 1 |
| Low probability of clinical worsening following switching biologic disease-modifying antirheumatic drug in patients wiith rheumatoid arthritis and partial response to adalimumab | SANOFI-AVENTIS U.S. LLC | $30.55 | 1 |
About Dr. Vibeke Strand, M.D
Dr. Vibeke Strand, M.D is a Rheumatology healthcare provider based in Portola Valley, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/02/2007. The National Provider Identifier (NPI) number assigned to this provider is 1194882753.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Vibeke Strand, M.D has received a total of $1.4M in payments from pharmaceutical and medical device companies, with $60,263 received in 2024. These payments were reported across 916 transactions from 45 companies. The most common payment nature is "Consulting Fee" ($929,387).
Ad
Practice Information
- Specialty Rheumatology
- Location Portola Valley, CA
- Active Since 01/02/2007
- Last Updated 07/08/2007
- Taxonomy Code 207RR0500X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1194882753
Products in Payments
- XELJANZ (Drug) $179,352
- COSENTYX (Biological) $117,132
- Sprifermin (Biological) $52,399
- Humira (Biological) $41,174
- KEVZARA SARILUMAB INJECTION (Biological) $38,945
- KEVZARA (Drug) $35,909
- KRYSTEXXA (Biological) $35,144
- Zilretta (Drug) $30,679
- SKYRIZI (Biological) $27,288
- ORENCIA (Biological) $26,535
- KEVZARA (Biological) $24,892
- Tavneos (Drug) $23,385
- INFLECTRA (Biological) $18,013
- Enbrel (Biological) $17,933
- TALTZ (Drug) $15,088
- SAPHNELO (Biological) $13,563
- Essure (Device) $13,397
- Actemra (Biological) $13,309
- STELARA (Biological) $11,990
- CEC_COSENTYX_IMMUNOLOGY (Biological) $9,735
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.